{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:05:05Z","timestamp":1747181105542,"version":"3.40.5"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T00:00:00Z","timestamp":1671753600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,23]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Macrophage activation syndrome (MAS), or secondary hemophagocytic lymphocytosis (sHLH), is a rare systemic inflammatory response syndrome that is fatal. Adult patients lack clear criteria for diagnosis and treatment, primarily derived from guidelines and protocols for treating family hemophagocytic lymphocytosis and systemic juvenile idiopathic arthritis (sJIA)-related MAS in children or from retrospective case reports. As a subtype of sHLH, MAS has a clinical presentation like sHLH, but treatment varies. Herein, we report the case of a 40-year-old female with MAS caused by a connective tissue disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>The patient presented to the Rheumatology and Immunology Clinic with recurrent fever and rash, and MAS was confirmed after a series of examinations. The patient had no significant effect after treatment with JAK inhibitors, but after the use of the IL-6 inhibitor tocilizumab, the fever and rash were significantly reduced, and laboratory indicators returned to normal levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Considering the patient\u2019s condition and laboratory test results, we judged that the patient had connective tissue disease with MAS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>We gave sequential treatment of tocilizumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>ALL indicators are mostly back to normal when the patient was monitored at the outpatient clinic.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>MAS\/HLH lacks clear criteria for diagnosis or treatment in adult patients and is extremely difficult to distinguish from bacterial sepsis or other systemic inflammatory response syndromes. Consequently, early diagnosis and treatment are indispensable for enhancing patient survival.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032426","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T14:04:53Z","timestamp":1672149893000},"page":"e32426","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Connective tissue disease with macrophage activation syndrome: A case report"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8162","authenticated-orcid":false,"given":"Qu","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Binzhou Medical University Hospital, Binzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiushuang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Binzhou Medical University Hospital, Binzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuebin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Binzhou Medical University Hospital, Binzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00296-020-04636-y","article-title":"Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.","volume":"41","author":"Soy","year":"2021","journal-title":"Rheumatol Int"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome.","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41435-020-0098-4","article-title":"The genetics of macrophage activation syndrome.","volume":"21","author":"Schulert","year":"2020","journal-title":"Genes Immun"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"e933272","DOI":"10.12659\/AJCR.933272","article-title":"spontaneous recovery of hemophagocytic lymphohistiocytosis due to primary epstein-barr virus infection in an adult patient.","volume":"22","author":"Matsuo","year":"2021","journal-title":"Am J Case Rep"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"101515","DOI":"10.1016\/j.berh.2020.101515","article-title":"Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy.","volume":"34","author":"Griffin","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.","volume":"133","author":"La Rosee","year":"2019","journal-title":"Blood"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/asheducation-2018.1.313","article-title":"The rheumatology\/hematology interface: CAPS and MAS diagnosis and management.","volume":"2018","author":"Gansner","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/rheumatology\/key006","article-title":"Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment.","volume":"58","author":"Carter","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.5045\/br.2021.2020323","article-title":"Current status of the diagnosis and treatment of hemophagocytic lymphohistiocytosis in adults.","volume":"56","author":"Kim","year":"2021","journal-title":"Blood Res"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pbc.24188","article-title":"Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.","volume":"60","author":"Marsh","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients.","volume":"50","author":"Miettunen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12969-020-0399-1","article-title":"Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.","volume":"18","author":"Shimizu","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3389\/fimmu.2018.02162","article-title":"Rapamycin as an adjunctive therapy for NLRC4 associated macrophage activation syndrome.","volume":"9","author":"Barsalou","year":"2018","journal-title":"Front Immunol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.38802","article-title":"Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.","volume":"66","author":"Minoia","year":"2014","journal-title":"Arthritis Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:25:26Z","timestamp":1746336326000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":14,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032426","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,12,23]]}}}